Conventional chemotherapy is ineffective in the majority of @entity1 with @entity3052 ( @entity3052 ), and monoclonal antibodies recognising @entity1116 expressed on myeloid progenitors (e.g. @entity24098 (GO)) have been reported to improve outcome in @entity1 with @entity3052 . Reports of excess @entity137 have resulted in GO's licence being withdrawn. As a result, the role of these agents remains unclear. A systematic review and meta-analysis included studies of @entity1 with @entity3052 who had entered a randomised control trial (RCT), where one arm included anti- @entity1116 antibody therapy. Fixed effect meta-analysis was used, involving calculation of observed minus expected number of events, and variance for each endpoint in each trial, with the overall treatment effect expressed as Peto's odds ratio with 95  % confidence interval. Meta-analysis of 11 RCTs with 13 randomisations involving GO was undertaken. Although GO increased induction deaths (p   =   0.02), it led to a reduction in resistant disease (p   =   0.0009); hence, there was no improvement in complete remission. Whilst GO improved relapse-free survival (hazard ratio (HR)   =   0.90, 95  % confidence interval (CI)   =   0.84-0.98, p   =   0.01), there was no overall benefit of GO in @entity1349 ( @entity1349 ) (HR   =   0.96, 95  % CI   =   0.90-1.02, p   =   0.2). GO improved @entity1349 in @entity1 with favourable cytogenetics, with no evidence of benefit in @entity1 with intermediate or adverse cytogenetics (test for heterogeneity between subtotals p   =   0.01). GO has a potent clinically detectable anti-leukaemic effect. Further trials to investigate its optimum delivery and identification of @entity1 populations who may benefit are needed.

Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti- @entity1116 antibody treatment in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity24098 :: ('MESH:C406061', 'Chemical') :: ['gemtuzumab  ozogamicin'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukaemia', 'AML'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity1116 :: ('945', 'Gene') :: ['CD33']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukaemia']
